Hormetic Stress Biohacking Type 1 Diabetes CGM

Image
Photo: Unsplash.com Medical Disclaimer : The content on this blog is purely for informational purposes only. For medical advice, diagnosis and treatment, consult your doctor. The ultimate goal for anyone living with Type 1 Diabetes (T1D) is stability. You want fewer spikes, fewer crashes, and more time spent in your target blood sugar range. Read more on blood sugar spike . For years, standard medical advice focused purely on matching insulin doses to carbohydrate intake. While this foundational math is necessary, it often leaves people riding a frustrating blood sugar roller coaster. Today, a new wave of tech-savvy individuals is looking beyond the traditional playbook. They are combining the principles of biohacking, the physiological benefits of hormetic stress, and the real-time data of Continuous Glucose Monitors (CGMs) to transform how they manage their health. This approach does not replace insulin. Instead, it aims to make the body more resilient, predictable, and res...

U.S. FDA Approves Kresladi Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I in Pediatric Patients

Dr. Vinay Prasad


The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Kresladi, a groundbreaking gene therapy for treating severe Leukocyte Adhesion Deficiency Type I (LAD-I) in pediatric patients. 

This approval marks a significant milestone, making Kresladi the first FDA-approved gene therapy for this rare, life-threatening immune deficiency.

What is Severe LAD-I?

Severe LAD-I is a rare genetic disorder caused by mutations in the ITGB2 gene, leading to recurrent, life-threatening infections. Patients often face significant morbidity and mortality in their first decade.

How Kresladi Works

Kresladi is an autologous hematopoietic stem cell-based gene therapy that introduces functional ITGB2 gene copies, restoring CD18 and CD11a expression in white blood cells. This addresses the underlying cause of severe LAD-I, enhancing immune function.

Efficacy and Safety

Approval was based on a single-arm study showing increased neutrophil CD18 and CD11a expression, indicating improved immune activity. Common side effects included anemia, low blood cell counts, and infections. Post-marketing studies will confirm clinical benefits.

FDA's Commitment to Rare Diseases

"The FDA continues to advance innovative gene therapies for rare pediatric diseases," said Dr. Vinay Prasad, FDA's Center for Biologics Evaluation and Research. Kresladi received Orphan Drug, Rare Pediatric Disease, and Fast Track designations.

Impact on Patients

"Kresladi offers a potentially transformative treatment option," said Dr. Megha Kaushal, FDA. "This treatment can improve quality of life for children with severe LAD-I."

Rocket Pharmaceuticals, Inc. received accelerated approval and a Rare Pediatric Disease Priority Review Voucher.

Comments

Popular posts from this blog

The Impressive Health Benefits of Pumpkin Seeds

The Grave Consequences of Attacking Health Sites in Iran

Why Gastric Ulcer Patients Should Avoid Tomatoes and Tomato-Based Products